251 related articles for article (PubMed ID: 33549556)
21. Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure.
Ferreira JP; Santos M; Almeida S; Marques I; Bettencourt P; Carvalho H
Eur J Intern Med; 2014 Jan; 25(1):67-72. PubMed ID: 24070521
[TBL] [Abstract][Full Text] [Related]
22. Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients.
Donderski R; Stróżecki P; Sulikowska B; Grajewska M; Miśkowiec I; Stefańska A; Siódmiak J; Odrowąż-Sypniewska G; Manitius J
Int Urol Nephrol; 2017 Oct; 49(10):1867-1873. PubMed ID: 28710615
[TBL] [Abstract][Full Text] [Related]
23. [Aldosterone and its antagonists in heart failure].
Lopes ME; Le Corvoisier P; Tabet JY; Su JB; Badoual T; Cachin JC; Merlet P; Castaigne A; Hittinger L
Presse Med; 2003 Jan; 32(2):79-87. PubMed ID: 12653034
[TBL] [Abstract][Full Text] [Related]
24. Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.
Yang P; Shen W; Chen X; Zhu D; Xu X; Wu T; Xu G; Wu Q
Heart Fail Rev; 2019 Sep; 24(5):637-646. PubMed ID: 31030322
[TBL] [Abstract][Full Text] [Related]
25. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Zannad F; Dousset B; Alla F
Hypertension; 2001 Nov; 38(5):1227-32. PubMed ID: 11711528
[TBL] [Abstract][Full Text] [Related]
26. A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial.
Elinoff JM; Rame JE; Forfia PR; Hall MK; Sun J; Gharib AM; Abd-Elmoniem K; Graninger G; Harper B; Danner RL; Solomon MA
Trials; 2013 Apr; 14():91. PubMed ID: 23547564
[TBL] [Abstract][Full Text] [Related]
27. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA;
Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133
[TBL] [Abstract][Full Text] [Related]
28. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial.
Ravassa S; López B; Ferreira JP; Girerd N; Bozec E; Pellicori P; Mariottoni B; Cosmi F; Hazebroek M; Verdonschot JAJ; Cuthbert J; Petutschnigg J; Moreno MU; Heymans S; Staessen JA; Pieske B; Edelmann F; Clark AL; Cleland JGF; Zannad F; Díez J; González A;
Eur J Heart Fail; 2022 Feb; 24(2):321-331. PubMed ID: 34841615
[TBL] [Abstract][Full Text] [Related]
29. Effect of spironolactone for 1 yr on endothelial function and vascular inflammation biomarkers in renal transplant recipients.
Mortensen LA; Bistrup C; Stubbe J; Carlström M; Checa A; Wheelock CE; Palarasah Y; Bladbjerg EM; Thiesson HC; Jensen BL
Am J Physiol Renal Physiol; 2019 Sep; 317(3):F529-F539. PubMed ID: 31166706
[TBL] [Abstract][Full Text] [Related]
30. Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial.
Yu YL; Siwy J; An DW; González A; Hansen T; Latosinska A; Pellicori P; Ravassa S; Mariottoni B; Verdonschot JA; Ahmed F; Petutschnigg J; Rossignol P; Heymans S; Cuthbert JJ; Girerd N; Clark AL; Verhamme P; Nawrot TS; Janssens S; Cleland JG; Zannad F; Diez J; Mischak H; Ferreira JP; Staessen JA;
Heart; 2024 May; ():. PubMed ID: 38729636
[TBL] [Abstract][Full Text] [Related]
31. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial.
Desai AS; Liu J; Pfeffer MA; Claggett B; Fleg J; Lewis EF; McKinlay S; O'Meara E; Shah SJ; Sweitzer NK; Solomon S; Pitt B
J Card Fail; 2018 May; 24(5):313-320. PubMed ID: 29572190
[TBL] [Abstract][Full Text] [Related]
32. Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation.
Esposito CT; Varahan S; Jeyaraj D; Lu Y; Stambler BS
J Cardiovasc Electrophysiol; 2013 Jul; 24(7):806-12. PubMed ID: 23489714
[TBL] [Abstract][Full Text] [Related]
33. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016.
Buysse JM; Huang IZ; Pitt B
Future Cardiol; 2012 Jan; 8(1):17-28. PubMed ID: 22185443
[TBL] [Abstract][Full Text] [Related]
34. Determinants of the beneficial effect of mineralocorticoid receptor antagonism on exercise capacity in heart failure with reduced ejection fraction.
Dankowski R; Kotwica T; Szyszka A; Przewłocka-Kosmala M; Sacharczuk W; Karolko B; Kobusiak-Prokopowicz M; Mysiak A; Kosmala W
Kardiol Pol; 2018; 76(9):1327-1335. PubMed ID: 29862486
[TBL] [Abstract][Full Text] [Related]
35. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
[TBL] [Abstract][Full Text] [Related]
36. Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.
Vardeny O; Claggett B; Vaduganathan M; Beldhuis I; Rouleau J; O'Meara E; Anand IS; Shah SJ; Sweitzer NK; Fang JC; Desai AS; Lewis EF; Pitt B; Pfeffer MA; Solomon SD;
JACC Heart Fail; 2019 Dec; 7(12):1022-1028. PubMed ID: 31779923
[TBL] [Abstract][Full Text] [Related]
37. Aldosterone antagonism and congestive heart failure: a new look at an old therapy.
Thohan V; Torre-Amione G; Koerner MM
Curr Opin Cardiol; 2004 Jul; 19(4):301-8. PubMed ID: 15218387
[TBL] [Abstract][Full Text] [Related]
38. Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction.
Kuno T; Ueyama H; Fujisaki T; Briasouli A; Takagi H; Briasoulis A
Am J Cardiol; 2020 Apr; 125(8):1187-1193. PubMed ID: 32081366
[TBL] [Abstract][Full Text] [Related]
39. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?
Bansal S; Lindenfeld J; Schrier RW
Circ Heart Fail; 2009 Jul; 2(4):370-6. PubMed ID: 19808361
[TBL] [Abstract][Full Text] [Related]
40. Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction.
Selvaraj S; Claggett B; Shah SJ; Anand IS; Rouleau JL; Desai AS; Lewis EF; Vaduganathan M; Wang SY; Pitt B; Sweitzer NK; Pfeffer MA; Solomon SD
Circ Heart Fail; 2019 Jul; 12(7):e006125. PubMed ID: 31220936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
